Cargando…

Biosimilars: Current regulatory perspective and challenges

Detalles Bibliográficos
Autores principales:	Jha, Diwakar, Mishra, Ram Kumar, Pandey, Rishabh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612345/ https://www.ncbi.nlm.nih.gov/pubmed/23559830 http://dx.doi.org/10.4103/0975-7406.106569

Ejemplares similares

Current perspectives on biosimilars
por: Agbogbo, Frank K., et al.
Publicado: (2019)

Perspective, perceptions, and promulgation of biosimilars: A questionnaire-based study to assess and understand the current challenges of biosimilars to the potential and intended users
por: Bhardwaj, Krishan Kumar, et al.
Publicado: (2020)

Biosimilars: a regulatory perspective from America
por: Kay, Jonathan
Publicado: (2011)

Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities
por: Rahalkar, Hasumati, et al.
Publicado: (2021)

Biosimilars: Current perspectives and future implications
por: Misra, Monika
Publicado: (2012)

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015)

Regulatory challenges with biosimilars: an update from 20 countries
por: Kang, Hye‐Na, et al.
Publicado: (2020)

The biosimilars journey: current status and ongoing challenges
por: Kos, Igor Age, et al.
Publicado: (2018)

Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence”
por: Finck, Barbara, et al.
Publicado: (2021)

Biosimilars in India; Current Status and Future Perspectives
por: Meher, Bikash R., et al.
Publicado: (2019)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Biosimilars: The naming puzzle
por: Gaur, Rajneesh Kumar
Publicado: (2015)

Biosimilar drugs: Current status
por: Kumar, Rajiv, et al.
Publicado: (2014)

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Ophthalmic biosimilars: Lessons from India
por: Sharma, Ashish, et al.
Publicado: (2019)

Biosimilars in Oncology: Latest Trends and Regulatory Status
por: Joshi, Deeksha, et al.
Publicado: (2022)

On the Regulatory Approval Pathway of Biosimilar Products
por: Wang, Jun, et al.
Publicado: (2012)

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
por: Park, Sang Hyoung, et al.
Publicado: (2020)

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
por: Declerck, Paul, et al.
Publicado: (2017)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
por: Rawla, Prashanth, et al.
Publicado: (2018)

Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in Brazil
por: de Assis, Marcos Renato, et al.
Publicado: (2018)

The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
por: Chang, Lin-Chau
Publicado: (2019)

Current Status of Biosimilar Growth Hormone
por: Saenger, Paul
Publicado: (2009)

Current status and considerations on biosimilar in China
por: Wang, Junzhi
Publicado: (2012)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Challenges of Integrating Biosimilars Into Clinical Practice
por: Jeffers, Kate, et al.
Publicado: (2020)

Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021)

Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
por: Kumar, Aman, et al.
Publicado: (2021)

Biosimilar insulins: a European perspective
por: DeVries, J H, et al.
Publicado: (2015)

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023)

Regulatory evaluation of biosimilars throughout their product life-cycle
por: Kang, Hye-Na, et al.
Publicado: (2018)

Biosimilars: Key regulatory considerations and similarity assessment tools
por: Kirchhoff, Carol F., et al.
Publicado: (2017)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
por: Halimi, Vesa, et al.
Publicado: (2020)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
por: Gupta, Ranjan
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3tgjn3jmv12q0rsq963erk5to6